



## News Release

**Contacts:** Andrew Markwick, QuintilesIMS Investor Relations ([andrew.markwick@quintilesims.com](mailto:andrew.markwick@quintilesims.com))  
+1.973.257.7144

Tor Constantino, QuintilesIMS Media Relations ([tor.constantino@quintilesims.com](mailto:tor.constantino@quintilesims.com))  
+1.484.567.6732

### QuintilesIMS Statement Regarding Belgian Hospital Data

**BRUSSELS, Belgium** – October 6, 2017 – QuintilesIMS helps healthcare decision makers globally, use healthcare data to deliver critical, real-world disease and treatment insights. For more than sixty years, QuintilesIMS has pioneered the use of non-identifiable data in research. The goal is to ensure patients and the healthcare system benefit from data-driven healthcare decisions while also protecting privacy.

We take patient privacy very seriously and are committed to complying with the laws and regulations in the countries where we operate. Regarding Belgian hospital data referenced in recent media stories, we only receive and use non-identified records to report aggregate statistics regarding healthcare trends – **no identified patient data** is used by QuintilesIMS for these services. These hospitals provide information to QuintilesIMS on a non-identified basis. We only provide aggregate statistics from this data with respect to topics such as diagnoses, treatments, costs and population health.

There are several benefits and uses of this data specific to the Belgian market and broader society including:

- Hospital benchmarking which enables point-of-care facilities to better understand and implement enhanced patient treatment using an aggregated data-driven approach.
- Identifying effective therapeutic options for insurer formularies, reimbursement dossiers and health economics evaluations that convey the best value and outcomes for local healthcare systems.
- Providing real-world insights derived from actual clinical settings regarding unmet therapeutic needs and diseases to pinpoint new areas to help advance healthcare research and development.
- Scientific research to support development of provider treatment guidelines and understand specific incidence of various conditions among Belgian populations such as:
  - A study presented to the Belgian Society of Haematology regarding two types of hematopoietic stem cell transplantations and outcomes.
  - Research presented to the Belgian Endocrinian Society regarding ophthalmologic complications (e.g. glaucoma, retinopathy, cataract) in Belgian patients with type I or type II diabetes who undergo surgical treatment.

- Findings presented to Belgian Society of Medical Oncology that explored treatment protocols/ guidelines of chemotherapy regimens as first-line treatment in patients with non-resectable/ metastatic colorectal cancers (mCRC).

In addition to the above, QuintilesIMS information is used in a wide range of public research performed by researchers at the QuintilesIMS Institute for Healthcare Informatics, university researchers and others. More information about this public research can be found at: [http://www.imshealth.com/files/web/IMSH%20Institute/QI\\_Institute\\_Bibliography.pdf](http://www.imshealth.com/files/web/IMSH%20Institute/QI_Institute_Bibliography.pdf). These many uses provide benefits to the Belgium health system, insurers, hospitals and local patients.

### **About QuintilesIMS**

QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS's approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS's broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes.

As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward.

# # #